Janux's Prostate Cancer Drug Shows Declining Response Rates in Early Trial Data
Janux Therapeutics' (JANX) JANX007 immunotherapy disappoints with only 30% response rate in heavily pre-treated prostate cancer patients, raising concerns about efficacy.